Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

APL 3007

Next Previous
Drug Profile

APL 3007

Alternative Names: APL-3007

Latest Information Update: 22 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apellis Pharmaceuticals
  • Class Eye disorder therapies; Small interfering RNA
  • Mechanism of Action Complement C3 expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Age-related macular degeneration

Most Recent Events

  • 14 May 2026 Apellis Pharmaceuticals has been acquired by Biogen
  • 23 Jun 2025 Phase-II clinical trials in Age-related macular degeneration(Treatment-experienced, Combination therapy) in USA (SC) (NCT07215390)
  • 28 Feb 2025 Apellis Pharmaceuticals plans a phase II trial in Age-related macular degeneration (Combination thearpy) in 2Q 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top